AbbVie Inc. Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
AbbVie Inc. (ABBV) reported Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents of -$19.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Change in Cash
us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-03
- AbbVie Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2026-03-31 was -$12.00M, a 233.33% decline year-over-year.
- AbbVie Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2025-03-31 was $9.00M.
- AbbVie Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2024-03-31 was -$18.00M, a 325.00% decline year-over-year.
- AbbVie Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2023-03-31 was $8.00M, a 14.29% increase year-over-year.
- AbbVie Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2025 was $42.00M.
- AbbVie Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2024 was -$65.00M, a 1400.00% decline from fiscal 2023.
- AbbVie Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2023 was $5.00M.
- AbbVie Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2022 was -$62.00M.
| Period end | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$19.00M 10-Q · filed 2026-08-03 | |||
| 2026-03-31 | -$12.00M 10-Q · filed 2026-05-08 | |||
| 2025-12-31 | $42.00M 10-K · filed 2026-02-20 | |||
| 2025-09-30 | $31.00M 10-Q · filed 2025-11-04 | |||
| 2025-06-30 | $39.00M 10-Q · filed 2026-08-03 | |||
| 2025-03-31 | $9.00M 10-Q · filed 2026-05-08 | |||
| 2024-12-31 | -$65.00M 10-K · filed 2026-02-20 | |||
| 2024-09-30 | -$19.00M 10-Q · filed 2025-11-04 | |||
| 2024-06-30 | -$27.00M 10-Q · filed 2025-08-04 | |||
| 2024-03-31 | -$18.00M 10-Q · filed 2025-05-09 | |||
| 2023-12-31 | $5.00M 10-K · filed 2026-02-20 | |||
| 2023-09-30 | -$18.00M 10-Q · filed 2024-11-04 | |||
| 2023-06-30 | -$2.00M 10-Q · filed 2024-08-07 | |||
| 2023-03-31 | $8.00M 10-Q · filed 2024-05-03 | |||
| 2022-12-31 | -$62.00M 10-K · filed 2025-02-14 | |||
| 2022-09-30 | -$85.00M 10-Q · filed 2023-11-06 | |||
| 2022-06-30 | -$26.00M 10-Q · filed 2023-08-07 | |||
| 2022-03-31 | $7.00M 10-Q · filed 2023-05-05 | |||
| 2021-12-31 | -$97.00M 10-K · filed 2024-02-20 | |||
| 2021-09-30 | -$69.00M 10-Q · filed 2022-11-04 | |||
| 2020-12-31 | -$5.00M 10-K · filed 2023-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |